Nuclear Medicine Radioisotopes Market Report 2025

The nuclear medicine radioisotopes market size has grown strongly in recent years. It will grow from $8.21 billion in 2024 to $8.85 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to discovery of radioactivity, emergence of nuclear medicine, therapeutic applications, clinical research, and patient demand.

The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $11.96 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing healthcare spending, expansion of healthcare infrastructure, growing awareness of environmental sustainability, education campaigns and awareness programs and growth in medical tourism. Major trends in the forecast period include development of new radioisotopes, production and supply chain innovations, microfluidics and lab-on-a-chip technology, artificial intelligence in radiopharmaceutical development and nanotechnology.

The forecast of 7.8% growth over the next five years reflects a modest reduction of 0.7% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade disruptions could cripple U.S. diagnostic imaging by increasing costs of technetium-99m and lutetium-177 sourced from Canada and South Africa, resulting in delayed cancer staging and higher radiopharmaceutical procedure expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the nuclear medicine radioisotope market in the coming years. Cardiovascular diseases encompass a range of conditions that affect the heart and blood vessels. The rise in these diseases can be attributed to sedentary lifestyles, poor dietary habits, higher obesity rates, and aging populations. Nuclear medicine radioisotopes are essential in diagnosing, assessing, and managing cardiovascular diseases by providing detailed insights into cardiac function, perfusion, and tissue viability, which are crucial for accurate diagnoses and effective treatment planning. For example, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including around 4 million men and 3.6 million women. These diseases account for about 27% of all deaths in the UK, leading to over 170,000 deaths annually, or approximately 480 deaths per day, which equates to one death every three minutes. As a result, the rising incidence of cardiovascular diseases is fueling the growth of the nuclear medicine radioisotope market.

Key players in the nuclear medicine radioisotopes market are concentrating on developing innovative products such as compact low-energy cyclotrons to enhance the production and availability of radioisotopes, thereby ensuring more efficient and accessible diagnostic and therapeutic options. Compact low-energy cyclotrons are small particle accelerators used to create radioisotopes for medical imaging and treatments in nuclear medicine. For instance, in January 2022, IBA introduced Cyclone Key, a new accelerator designed to provide increased access to diagnostic solutions and enable in-house production of radiopharmaceuticals. Cyclone Key offers features such as a compact and efficient design, fully automated operation, multiple isotope production capabilities, ease of installation and operation, water cooling, self-shielding, and high performance, making it versatile and reliable.

In April 2024, Telix Pharmaceuticals Limited acquired ARTMS, a Canada-based company specializing in novel radioisotope technology. This acquisition aimed to bolster Telix Pharmaceuticals' nuclear medicine capabilities, optimize production procedures, and expand its range of diagnostic and therapeutic radiopharmaceuticals. ARTMS's innovative radioisotope technology holds promise for advancing nuclear medicine applications and addressing the growing demand for radiopharmaceuticals in the diagnosis and treatment of various medical conditions, including cardiovascular diseases.

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer Aktiengesellschaft, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacıbaşı-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation.

North America was the largest region in the nuclear medicine radioisotopes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nuclear medicine radioisotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nuclear medicine radioisotopes market consists of sales of yttrium-90, indium-111, carbon-11, samarium-153, and strontium-89. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The nuclear medicine radioisotopes research report is one of a series of new reports that provides nuclear medicine radioisotopes market statistics, including the nuclear medicine radioisotopes industry's global market size, regional shares, competitors with a nuclear medicine radioisotopes market share, detailed nuclear medicine radioisotopes market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine radioisotopes industry. This nuclear medicine radioisotopes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Radioactive isotopes, known as nuclear medicine radioisotopes, play crucial roles in diagnosing, treating, and researching diverse medical conditions. These isotopes emit radiation that specialized equipment detects and images, aiding in diagnosis, or administer therapeutic radiation doses to specific tissues. Integral to modern medical practices, nuclear medicine radioisotopes offer essential diagnostic information and therapeutic solutions, thereby enhancing patient outcomes.

Among the primary types of nuclear medicine radioisotopes are technetium-99m (Tc-99m), thallium-201 (Tl-201), iodine (I-123), fluorine-18, rubidium-82 (Rb-82), iodine-131 (I-131), lutetium-177 (Lu-177), radium-223 (Ra-223) and alpharadin, actinium-225 (Ac-225), and others. Technetium-99m (Tc-99m), widely employed in nuclear medicine imaging, facilitates the diagnosis of various medical conditions across oncology, cardiology, thyroid, neurology, and other fields. End users including hospitals, diagnostic centers, specialty clinics, as well as educational and research institutes, benefit from its applications.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.